 This is an open-label, single-arm, multicentre study which will enroll approximately 105 patients. Open-label means all people involved in the study know the identity of the intervention. Single-arm means there is one group of patients, all receiving the same treatment. Four 21-day cycles of a combination of bortezomib i.v. intravenous 1.3 mgm2 Days 1, 4, 8 and 11, doxorubicin i.v. 20 mgm2 days 1 and 4 and dexamethasone p.o. by mouth days 1, 2, 4, 5, 8, 9, 11 and 12 PAD will be given. Patients will be discontinued if disease progresses, or unacceptable treatment-related toxicity occurs. Following PAD treatment, patients will have peripheral blood stem cells PBSC collected, and an autologous stem cell transplant ASCT will be performed. Patients will then make monthly visits to the Study Doctor until 1 year after start of treatment, and attend a final follow-up visit at 2 years. Efficacy assessment of response to PAD will be made using the International Myeloma Working Group IMWG criteria. The primary outcome is to compare the overall response rate following 4 cycles of PAD induction therapy between patients with and without extra copies of the long arm of the first chromosome 1q21 measured by fluorescent in situ hybridisation FISH in their marrow at baseline. Patient reported outcomes will be assessed using the AQoL Assessment of Quality of Life. Safety will be evaluated throughout the study by assessment of adverse events including changes in physical examination, concomitant medication, ECOG Eastern Cooperative Oncology Group scores, vital signs and clinical laboratory findings. A sample size of 105 provides 80 power a0.05 to detect a difference in overall response rate of 28 at the end of 4 cycles of PAD. This is based on the assumptions that 44 of patients have amplification of 1q21 1, 2, the overall response rate with PAD combination therapy is 80; the overall response rate with PAD if PAD therapy does not overcome 1q21 amplification is assumed to be 64, while without 1q21 amplification it is assumed to be 92. That is: Overall Response Rate ORR P1q21 amplified x ORRamplified P1q21 not amplified x ORRnot amplified i.e. 80 44 x 64 56 x 92. The sample size of 105 allows for a 20 drop-out rate. Four 21-day cycles of PAD: a combination of bortezomib i.v. intravenous 1.3 mgm2 Days 1, 4, 8 and 11, doxorubicin i.v. 20 mgm2 days 1 and 4 and dexamethasone p.o. by mouth days 1, 2, 4, 5, 8, 9, 11 and 12. 